

Entresto (Sacubitril-Valsartan)

INDICATION: To reduce the cardiovascular death and hospitalization for heart failure patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction

HOW SUPPLIED: 24 mg - 26 mg tablet, 49 mg - 51 mg tablet, 97 mg - 103 mg tablet

DAILY DOSING: Administer tablets twice daily, with or without food

- The recommended starting dose of ENTRESTO is 49/51 mg (sacubitril/valsartan) twice-daily. Double the dose of ENTRESTO after 2 to 4 weeks to the target maintenance dose of 97/103 mg (sacubitril/valsartan) twice-daily, as tolerated by the patient.
- Reduce the starting dose to 24/26 mg (sacubitril/valsartan) twice-daily for: patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low of these agents.
- patients with severe renal impairment (2.3) - patients with moderate hepatic impairment (2.4) Double the dose of ENTRESTO every 2 to 4 weeks to the target maintenance dose of 97/103 mg (sacubitril/valsartan) twice-daily, as tolerated by the patient

CONTRAINDICATIONS:

- Contraindicated in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy.
- Concomitant use with Tekturna (Aliskiren) in patients with diabetes.

WARNINGS and PRECAUTIONS:

- Contraindicated in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy.
- Concomitant use with Tekturna (Aliskiren) in patients with diabetes.

ADVERSE REACTIONS:

- Angioedema – **IMMEDIATELY DISCONTINUE**
- Hypotension
- Dizziness
- Decreased renal function
- Hyperkalemia
- Cough

DRUG INTERACTIONS:

- Dual blockade of the renin-angiotensin system: Do not use with an ACEi, do not use with Aliskiren in patients with diabetes, and avoid use with an ARB.
- Caution use of potassium sparing diuretics, potassium supplements and salt substitutes as it can increase serum potassium levels
- Caution use of NSAIDs as it can increase the risk of renal impairment
- Caution use of lithium as it can increase risk of lithium toxicity

USE IN SPECIFIC POPULATIONS:

RENAL IMPAIRMENT

- eGFR \geq 30 mL/min/1.73 m²: No dosage adjustment needed.
- eGFR < 30 mL/min/1.73 m²: Initiate therapy with sacubitril 24 mg/valsartan 26 mg PO twice daily. Double the dose every 2–4 weeks to the target maintenance dose of sacubitril 97 mg/valsartan 103 mg PO twice daily, as tolerated.


HEPATIC IMPAIRMENT

- Moderate impairment (Child-Pugh Class B) – Initiate Entresto 24mg/26mg twice a day. Double the dose every 2-4 weeks to target maintenance dose of 97mg/103mg as tolerated

SEVERE IMPAIRMENT – USE NOT RECOMMENDED

For Complete Prescribing Information:

<https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/entresto.pdf>



What Is Heart Failure?

The name doesn't mean your heart stops- It just doesn't work as well as it should. It happens when the heart muscle is weakened and can't pump enough blood, oxygen and nutrients to meet the body's needs. Eventually, fluid builds up in the arms, legs, ankles, feet, lungs, or other organs, the body becomes congested, and congestive heart failure is the term used to describe the condition.

Show What You Know

Entresto Quiz

1) True or False

Entresto is indicated for use in patients with a diagnosis of Atrial Fibrillation.

2) True or False

Entresto is contraindicated in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy.

3) True or False

Drug Interactions to include Potassium supplements, NSAIDs, Tekturna and Lithium

4) Adverse reactions to Entresto include all but one listed below.

Please indicate wrong answer:

- A. Angioedema
- B. Hypotension
- C. Hypokalemia
- D. Cough
- E. Decreased renal function

3) True or False

CHF stands for “Considered Heart Failure”

Quiz Answers- How Did You Do?

1. FALSE- Entresto is indicated for CHF
2. TRUE
3. TRUE
4. C - HYPOKALEMIA
5. FALSE- CHF stands for “Congestive (or Chronic) Heart Failure”